35 results about "Valvular heart disease" patented technology

The present invention provides methods for preventing or treating a valvular stenosis or a valvular calcification in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide / phospholipid complex, wherein the peptide of the complex is an Apolipoprotein A-1 mimetic peptide. In one embodiment the Apolipoprotein A-1 mimetic peptide has the sequence set forth in SEQ ID NO: 1. In another embodiment the phospholipid of the complex is egg sphingomyelin and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine.

A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide / phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

The invention discloses a bionic modified valve material and its preparation method and application, comprising the following steps: A. synthesizing drug-loaded nanoparticles loaded with drugs; B. preparing cell membrane vesicles; C. combining drug-loaded nanoparticles with cell membrane vesicles Bubble mixing and extruding for multiple times to prepare cell membrane-wrapped drug-loaded nanoparticles; D. cross-linking cell membrane-wrapped drug-loaded nanoparticles to the surface of the biovalve to obtain the final product. The method of the present invention has the advantages of simple operation, mild reaction conditions, etc., and the bionic modified valve material prepared by the method of the present invention wraps nanometer drug-loaded particles, which can well solve the problems of easy thrombosis, calcification and Endothelialization difficulties and other problems. At the same time, the strategy of combining the cell membrane bionic drug delivery system with the valve provides a new generation of treatment mode for the safe and efficient treatment of valvular heart disease.

The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, thrombosis, and calcification, (2) treating carcinoid heart disease, (3) identifying inhibitors of heart valve degeneration, thrombosis, and calcification, and (4) determining the safety of drugs.

Stretch-induced increased hemodynamic load adversely affects endothelial cell function and is an important contributor to thromboembolus formation in heart failure, valvular heart disease, atrial fibrillation, venous insufficiency, and pulmonary hypertension, and in thrombus occluded vein grafts. Local thrombus formation and thromboenbolic events can be reduced by inhibiting the TGF-beta signaling pathway or TGF-beta per se. Inhibitors can be administered to patients or veins (prior to interposition) at risk for thromboembolic events or local thrombus formation. Inhibitors can be applied to harvested veins to be used as arterial grafts.

The present invention provides modular transcatheter valve replacement devices and methods of using the same to treat valvular heart diseases. Disclosed is a bottom module that contains a heart valve replacement, and a top module connected to the bottom module. The top module may be bio-absorbable, or may contain one or more severable joints that allow the top module to be removed after implantation. The removable or absorbable top portion serves to add additional length the structure to add in orientation during implantation, but is removed or absorbed to minimize the metal and other foreign material in a patient's body that could cause thrombosis or other reactions.

The invention discloses a capsule for treating senile calcific valvular heart disease and a preparation method thereof, so as to solve the problem of cardiac valve calcification is difficult to treat. The preparation method is characterized by comprising the following steps: (1) distilling tetrapanax papyriferum, fruit of rosa davurica pall and littleflower stringbush bark and root through water vapor to extract volatile oil for standby, and storing the decoction dregs for standby; (2) crushing gecko and coked rice sprout into fine powder for standby; (3) uniformly mixing persimmon bark, sunglow, poncirus bark, horsetail, filipendula palmata (pall) maxim, fiveleaf akebia fruit and nakedflower beautyberry branchlet and leaf with the decoction dregs obtained in the step 1, extracting the mixture with alcohol for twice, mixing the two alcohol extracting solutions, filtering, recycling ethanol, and concentrating the filtrate to extract at reduced pressure; (4) adding the fine powder obtained in the step 2 in the extract obtained in the step 3, mixing evenly, drying the mixture at 60 DEG C, crushing the mixture into fine powder, adding polysorbate-80 in the mixture to prepare granules, drying, trimming the granules, spraying the volatile oil obtained in the step 1, mixing evenly, and filling a capsule with the mixture to obtain the capsule. Clinical experiments prove that the capsule for treating senile calcific valvular heart disease disclosed by the invention has the advantages of good curative effect and high safety, so that the capsule is worthy of clinical application and popularization.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.